Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane and Percutaneous Coronary Intervention by Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Both gender.~2. Patients with coronary artery disease candidates for coronary angioplasty stent.~3. Cardiac catheterization on an urgent basis.~4. Coronary angioplasty in elective and urgency.~5. Age less than 80 years.~Exclusion Criteria:~1. Patients aged greater than or equal of 80 years.~2. Angioplasty balloon catheter statement.~3. Myocardial infarction with ST-segment elevation.~4. Angioplasty in saphenous vein grafts in patients after surgical revascularization.~5. Patient pregnant.~6. Dialytic insufficiency renal.~7. Patients submited a urgent cardiac catheterization but not progress with coronary angioplasty stent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane Group (Type: EXPERIMENTAL): Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
- Control Group (Type: PLACEBO_COMPARATOR): Control Group called group B patients who will not receive sevoflurane. The patient of group B will receive facial mask properly attached to your face into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).